tradingkey.logo

Theravance Biopharma Inc

TBPH
View Detailed Chart

14.470USD

+0.420+2.99%
Close 09/18, 16:00ETQuotes delayed by 15 min
728.72MMarket Cap
55.92P/E TTM

Theravance Biopharma Inc

14.470

+0.420+2.99%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.99%

5 Days

+5.62%

1 Month

+6.32%

6 Months

+57.11%

Year to Date

+53.77%

1 Year

+74.97%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
8 / 175
Overall Ranking
60 / 4721
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 6 analysts
Buy
Current Rating
20.000
Target Price
+42.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 25.39% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 64.38M.
Overvalued
The company’s latest PE is 57.38, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 48.49M shares, decreasing 16.92% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.16M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.59.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
Ticker SymbolTBPH
CompanyTheravance Biopharma Inc
CEOMr. Rick E. Winningham
Websitehttps://www.theravance.com/
KeyAI